## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 1.39 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($86.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Nasdaq Tells Trump Crypto Partner Alt5 Sigma It ‘No Longer Meets’ Listing Requirements After Missed Report**
- Source: MSN | 20251206T230946 | Neutral | Relevance: 82%
- Nasdaq informed Alt5 Sigma, a partner to Donald Trump's crypto venture, that it no longer meets listing requirements due to failure to file its quarterly report. The company has until December 10 to submit a plan for regaining compliance. This warning comes as Alt5 Sigma is in a partnership to launch the "TrumpCoin" altcoin.

**2. Form 424B2 GOLDMAN SACHS GROUP INC**
- Source: StreetInsider | 20251208T190913 | Neutral | Relevance: 73%
-  Goldman Sachs Group Inc. has filed Form 424B2 for Autocallable Contingent Coupon Underlier-Linked Notes. These notes are linked to the Russell 2000 Index, Nasdaq-100 Technology Sector Index, and VanEck Semiconductor ETF, offering potential monthly coupons if underlier levels meet specific thresholds. The notes are subject to automatic redemption and significant risks, including the creditworthiness of GS Finance Corp. and The Goldman Sachs Group, Inc., and potential loss of the entire investment.

**3. Nasdaq panel grants Cambium Networks continued listing on global market**
- Source: Investing.com | 20251206T052215 | Neutral | Relevance: 64%
-  Cambium Networks Corporation (NASDAQ:CMBM) has been granted continued listing on The Nasdaq Global Market by the Nasdaq Hearings Panel, subject to conditions regarding its Minimum Bid Price Rule and Filing Rule compliance. The company, which has faced multiple non-compliance notices, must meet the Filing Rule by April 16, 2026, and the panel will monitor its adherence to the Minimum Bid Price Rule until April 8, 2026. Despite financial health concerns flagged by InvestingPro, the stock has shown significant price resilience recently.

**4. Miami International Holdings Reports Trading Results for March 2025; Options Volume Jumps 26.8% with MIAX Futures Volume Up 80.4%**
- Source: CBS 42 | 20251207T143134 | Somewhat-Bullish | Relevance: 64%
- Miami International Holdings (MIH) announced strong trading results for March 2025, with multi-listed options volume for the MIAX Exchange Group increasing by 26.8% year-over-year, reaching 173.6 million contracts. MIAX Futures also saw an 80.4% jump in monthly volume, totaling 309,006 contracts. The report highlights record year-to-date volumes for both options and futures, with MIAX Sapphire and MIAX Options achieving record monthly volumes and market shares.

**5. Basel Medical Group receives delinquency notification from Nasdaq**
- Source: MSN | 20251206T052321 | Neutral | Relevance: 64%
- Basel Medical Group announced it has received a delinquency notification from Nasdaq for failing to timely file its Form 10-Q for the quarter ended September 30, 2025. The company intends to submit a plan to regain compliance within 60 calendar days and expects to file the Form 10-Q as soon as practicable.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Morgan Stanley | $110 | $97 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.39 suggests fair value with growth premium. Forward P/E 23.6x stretched relative to 11% growth. Quality metrics strong (margin 20%). Analyst sentiment positive (1 raises, avg +13%). Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $51.5B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.63 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.39 |
| Forward P/E | 23.6 |
| Current P/E | 26.2 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.4% to -0.5% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.52% (CS: 50) | Neutral |
| RSI_14 | 56.2 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.050x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $89.80
- **Stop Loss:** $86.80 (3.3% risk)
- **Target:** $92.80 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 333
- **Position Value:** $29,903.40
- **Portfolio %:** 29.90%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*